1. 2021
  2. First-in-Human Phase I Clinical Trial of an SFV-Based RNA Replicon Cancer Vaccine against HPV-Induced Cancers

    Komdeur, F. L., Singh, A., van de Wall, S., Meulenberg, J. J. M., Boerma, A., Hoogeboom, B. N., Paijens, S. T., Oyarce, C., de Bruyn, M., Schuuring, E., Regts, J., Marra, R., Werner, N., Sluis, J., van der Zee, A. G. J., Wilschut, J. C., Allersma, D. P., van Zanten, C. J., Kosterink, J. G. W., Jorritsma-Smit, A., & 3 othersYigit, R., Nijman, H. W. & Daemen, T., 3 Feb 2021, In: Molecular therapy. 29, 2, p. 611-625 15 p.

    Research output: Contribution to journalArticleAcademicpeer-review

  3. Re-polarization of immunosuppressive macrophages to tumor-cytotoxic macrophages by repurposed metabolic drugs

    Oyarce, C., Vizcaino-Castro, A., Chen, S., Boerma, A. & Daemen, T., 2021, In: Oncoimmunology. 10, 1, 1898753.

    Research output: Contribution to journalArticleAcademicpeer-review

ID: 13455063